Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data in December disappointed the market.
Reuters reported earlier on Thursday that the Danish drugmaker will launch a new Phase III trial of the weekly injection on Feb. 10.
That trial will study the long-term efficacy of CagriSema and was already planned as part of the REDEFINE series, a spokesperson said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.